Department of Clinical Infectious Diseases, Aichi Medical University Hospital, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan.
Department of Infection Control, Aichi Medical University Hospital, Nagakute, Aichi, Japan.
BMC Immunol. 2020 Jun 5;21(1):33. doi: 10.1186/s12865-020-00362-z.
Presepsin (soluble CD14 subtype) is a novel biomarker of sepsis used for early diagnosis. Originally, CD14 is known as the pattern recognition receptor for the lipopolysaccharide (LPS)/LBP complexes, and the diagnostic value of this molecule for gram-positive bacteria, which contain less amount of LPS, is uncertain. To confirm its effectiveness in the diagnosis of bacteremia caused by gram positive bacteria, and to evaluate the interspecies difference of presepsin production against various bacterial strains, we conducted an in vitro assay to evaluate presepsin levels in response to five Gram negative and four Gram positive bacteria.
Whole blood was yielded from five healthy volunteers and co-cultured with bacterial strains at 37 °C for 4 h. Twenty seven clinical isolates of nine species (E. coli, K. pneumoniae, E. cloacae, P. aeruginosa, S. maltophilia, S. aureus, S. pyogenes, B. cereus, and C. striatum) derived from blood cultures of non-neutropenic bacteremia patients were used. Culture supernatants were harvested and presepsin levels were measured. The presepsin level in the gram-negative bacteria 273 (218-352) pg/mL was significantly higher than in the gram-positive bacteria 200 (143-275) pg/mL (p = 0.0002). The presepsin levels were significantly lower in C. striatum, in comparison to other bacteria, and S. pyogenes showed similar results. And the presepsin levels in P. aeruginosa were significantly lower compared to E. cloacae, K. pneumoniae, and S. aureus.
Presepsin production can also be evoked by gram-positive bacteria, and interspecies differences of presepsin response may exist, which should be considered in the diagnosis of sepsis, especially in certain gram-positive bacteremia such as S. pyogenes or C. striatum.
可溶性 CD14 亚型(Presepsin)是一种新型的用于早期诊断败血症的生物标志物。最初,CD14 被认为是脂多糖(LPS)/LBP 复合物的模式识别受体,而这种分子对革兰阳性菌(革兰阳性菌含有较少量的 LPS)的诊断价值尚不确定。为了确认其在诊断革兰阳性菌引起的菌血症中的有效性,并评估针对各种细菌株产生 Presepsin 的种间差异,我们进行了一项体外测定,以评估五种革兰氏阴性菌和四种革兰氏阳性菌对 Presepsin 水平的影响。
从五名健康志愿者中采集全血,并在 37°C 下与细菌株共培养 4 小时。使用了来自非中性粒细胞减少性菌血症患者血液培养物的 27 株临床分离株(9 种):大肠杆菌、肺炎克雷伯菌、阴沟肠杆菌、铜绿假单胞菌、嗜麦芽窄食单胞菌、金黄色葡萄球菌、化脓性链球菌、蜡样芽孢杆菌和 C. striatum。采集培养上清液并测量 Presepsin 水平。革兰氏阴性菌的 Presepsin 水平 273(218-352)pg/mL 明显高于革兰氏阳性菌的 200(143-275)pg/mL(p=0.0002)。C. striatum 的 Presepsin 水平明显低于其他细菌,而化脓性链球菌的结果与之相似。铜绿假单胞菌的 Presepsin 水平明显低于阴沟肠杆菌、肺炎克雷伯菌和金黄色葡萄球菌。
革兰氏阳性菌也可引发 Presepsin 产生,并且可能存在种间差异,在诊断败血症时应考虑这一点,特别是在某些革兰氏阳性菌血症(如化脓性链球菌或 C. striatum)中。